Cotec Healthcare Limited IPO Details

Incorporated in 1998, Cotec Healthcare Limited operates as a Contract Development and Manufacturing Organization (CDMO) with capabilities across 24 distinct formulation types. The company manufactures a wide range of products including injectables, tablets, capsules, ointments, eye drops, ampoules, vials, liquid and dry syrups, and infusions.

Its portfolio covers multiple therapeutic areas such as anaesthetics, analgesic/anti-inflammatory, antibiotics, anti-asthmatics, cardiovascular, dermatology, endocrinology and women’s health, clinical nutrition, vitamins, multivitamins, multimineral & supplements, and others.

The company’s manufacturing facility is located in Roorkee, Uttarakhand, covering 21,871.71 square meters, with an installed capacity of 4,051.38 million units as of March 31, 2025.

Cotec Healthcare Limited served 154, 177, and 122 customers during Fiscal 2025, 2024, and 2023, respectively. Key CDMO customers include Mankind Pharma Limited, German Remedies Pharmaceuticals Private Limited, Albert David Limited, Bion Therapeutics India Private Limited, Jagsonpal Pharmaceuticals Limited, and Makers Laboratories Limited.

The company’s operations span both domestic and international markets, supplying products across 24 states and union territories in India and exporting to 14 countries.

Cotec Healthcare Limited plans to expand exports to regions including Central Asia, Africa, the Commonwealth of Independent States, Latin America, Europe, and the Middle East.

As of August 31, 2025, Cotec Healthcare Limited employed 419 permanent employees and 203 contract workers.